POLR3E Antibody

What is POLR3E and why are antibodies against it important for research?

POLR3E is an 80kD subunit of RNA polymerase III (Pol III), which primarily functions in transcribing non-coding RNAs including tRNAs, 5S rRNA, and U6 snRNA. Antibodies against POLR3E have become important research tools for several reasons:

• They enable detection and quantification of this subunit in various experimental contexts

• They help elucidate the role of Pol III in both canonical transcription and non-canonical functions like viral DNA sensing

• They allow investigation of POLR3E in disease contexts, particularly in immune responses and autoimmune conditions

• They facilitate the study of transcriptional interference mechanisms involving Pol III

Recent research has revealed that POLR3E plays a critical role in innate immunity, particularly in sensing viral DNA and triggering type I interferon responses, making antibodies against it valuable for immunological research .

What are the main applications of POLR3E antibodies in research?

POLR3E antibodies have versatile applications in molecular and cellular research:

• Western Blotting (WB): Detection of endogenous POLR3E protein expression levels in various cell types and tissues, particularly useful for studying protein expression changes under different conditions

• Immunohistochemistry (IHC): Visualization of POLR3E distribution in tissue sections, enabling localization studies in normal and pathological tissues

• Immunofluorescence (IF)/Immunocytochemistry (ICC): Examination of subcellular localization of POLR3E in cultured cells

• ELISA: Quantitative measurement of POLR3E levels in biological samples

• Immunoprecipitation (IP): Isolation of POLR3E and its associated proteins to study protein-protein interactions and complexes

These techniques have enabled researchers to investigate POLR3E's roles in transcription regulation, viral response, and various disease contexts.

What characteristics should researchers look for when selecting a POLR3E antibody?

When selecting a POLR3E antibody for research applications, several key characteristics should be considered:

• Specificity: Ability to detect endogenous levels of POLR3E protein without cross-reactivity to other proteins, typically validated through western blot showing a single band at approximately 80 kDa

• Reactivity spectrum: Verified reactivity with specific species (human, mouse, rat, etc.) relevant to your research

• Applications validated: Confirmed performance in specific applications like WB, IHC, IF, ELISA, or IP

• Epitope location: Antibodies targeting different regions (N-terminal, internal region, C-terminal) may perform differently depending on protein conformation in your specific application

• Clonality: Polyclonal antibodies may offer broader epitope recognition, while monoclonal antibodies provide higher specificity for a single epitope

• Purification method: Affinity-purified antibodies generally offer higher specificity; many POLR3E antibodies are affinity-purified using epitope-specific immunogens

Commercial POLR3E antibodies have been validated through multiple techniques, including preabsorption with immunogen peptide to confirm specificity, as demonstrated in several immunostaining applications .

How should POLR3E antibodies be optimized for Western blot applications?

Optimizing POLR3E antibodies for Western blotting requires careful consideration of several parameters:

Protocol Optimization:

• Dilution range: Start with the manufacturer's recommended range (typically 1:500-1:2000 for POLR3E antibodies)

• Incubation time and temperature: For optimal signal-to-noise ratio, overnight incubation at 4°C is commonly used, though room temperature incubation for 1.5 hours has been successful in some protocols

• Blocking conditions: 5% non-fat milk or BSA in TBST is typically effective

• Detection method: Choose appropriate secondary antibodies and detection systems based on sensitivity requirements

Sample Preparation:

• Use appropriate lysis buffers that preserve protein integrity

• Include protease inhibitors to prevent degradation

• Determine optimal protein loading (typically 20-50 μg of total protein)

• Ensure complete denaturation and reduction of samples

Controls:

• Positive control: PC-3 cells have been validated as effective positive controls for POLR3E detection

• Negative control: Preabsorption with immunogen peptide or samples known to lack POLR3E expression

• Loading control: Use antibodies against housekeeping proteins like GAPDH or β-actin

When properly optimized, Western blotting with POLR3E antibodies should yield a distinct band at approximately 80 kDa, as observed in validation studies with PC-3 cells and other cell lines .

What are the best practices for using POLR3E antibodies in immunohistochemistry and immunofluorescence?

For optimal results in immunohistochemistry (IHC) and immunofluorescence (IF) with POLR3E antibodies:

Sample Preparation:

• For IHC: Use appropriate fixation (typically formalin) and paraffin embedding techniques, followed by proper deparaffinization and rehydration

• For IF: Proper fixation and permeabilization of cells is crucial for antibody accessibility to nuclear antigens like POLR3E

Antigen Retrieval:

• Heat-induced epitope retrieval (HIER) using high-pressure and temperature in Tris-EDTA buffer (pH 8.0) has been successfully employed for POLR3E antibodies in paraffin-embedded tissues

• Optimize retrieval time based on tissue type and fixation conditions

Antibody Dilution and Incubation:

• For IHC: Use dilutions in the range of 1:100-1:300

• For IF/ICC: Use dilutions in the range of 1:200-1:1000

• Incubate at 4°C overnight for optimal results, though incubation times may vary by protocol

Controls:

• Positive control: Human colon cancer tissue and breast carcinoma tissue have been validated as showing specific POLR3E staining

• Negative control: Pre-absorption of the antibody with immunogen peptide has been shown to effectively eliminate specific staining

• Additional controls: Include secondary antibody-only controls to assess background

Detection and Visualization:

• Use appropriate detection systems based on your microscopy setup

• For fluorescence, choose secondary antibodies with fluorophores suitable for your imaging system

• Include nuclear counterstaining for proper localization assessment

Successful staining should reveal primarily nuclear localization of POLR3E, consistent with its role in transcription, though cytoplasmic staining may also be observed in certain cell types .

How can researchers validate the specificity of POLR3E antibodies in their experimental systems?

Validating POLR3E antibody specificity is crucial for reliable experimental results. Comprehensive validation includes:

Multiple Technique Validation:

• Western blot analysis: Confirm a single band of expected molecular weight (~80 kDa) across different cell lines, with signal intensity corresponding to known expression levels

• Peptide competition assay: Pre-incubation of the antibody with the immunogen peptide should abolish specific signals in WB, IHC, and IF applications

• Knockout/knockdown validation: Compare signals between wild-type cells and those with POLR3E knockout or knockdown (e.g., using CRISPR/Cas9 or siRNA)

Cross-platform Consistency:

• Verify consistent localization patterns across different detection methods (IF, IHC)

• Compare results from different antibody clones targeting different epitopes of POLR3E

• Compare with published literature on POLR3E localization and expression

Additional Validation Methods:

• Mass spectrometry: Verify identity of immunoprecipitated protein

• Expression correlation: In transfection experiments, signal intensity should correlate with expression levels

• Cross-species reactivity: Test antibody performance across species claimed by manufacturer

A comprehensive validation approach as demonstrated in published studies includes immunoblotting across multiple cell lines, peptide competition assays in multiple applications (WB, IF, IHC), and careful comparison of staining patterns to expected subcellular localization .

How can POLR3E antibodies be used to investigate transcriptional interference mechanisms?

POLR3E antibodies provide valuable tools for investigating transcriptional interference mechanisms, particularly in the context of overlapping gene arrangements:

Chromatin Immunoprecipitation (ChIP) Applications:

• POLR3E antibodies can be used in ChIP assays to map Pol III occupancy on chromatin, especially at sites of potential interference with Pol II transcription

• This approach was crucial in studies showing that a mammalian interspersed repeat (MIR) embedded in antisense orientation within the first intron of the Polr3e gene affects its expression through transcriptional interference

• ChIP-seq with POLR3E antibodies can reveal genome-wide patterns of Pol III occupancy and potential interference sites

Functional Interference Studies:
Researchers can design experiments using POLR3E antibodies to:

• Identify Pol III occupancy at antisense elements within Pol II genes

• Correlate Pol III binding with changes in host gene expression

• Track changes in Pol III occupancy following genetic manipulation of embedded elements

For example, in mouse embryonic stem cells, CRISPR/Cas9-mediated deletion of an antisense MIR element in the Polr3e gene led to increased Polr3e expression at both mRNA and protein levels, with these changes detected using RT-qPCR and Western blotting with POLR3E antibodies .

Quantitative Analysis:
POLR3E antibodies enable quantitative assessment of how transcriptional interference affects POLR3E protein levels:

• Western blotting showed that deletion of the interfering MIR element resulted in approximately 1.5-fold increase in POLR3E protein levels

• This demonstrates how antibodies can help translate observations about transcriptional mechanisms to functional protein-level outcomes

This research highlights how POLR3E antibodies contribute to understanding complex regulatory mechanisms beyond simple protein detection.

What role does POLR3E play in innate immunity, and how can antibodies help study this function?

Recent research has uncovered a non-canonical role for RNA polymerase III, including the POLR3E subunit, in innate immunity as a sensor of viral DNA. POLR3E antibodies are essential tools for investigating this emerging function:

Studying POLR3E in Viral Sensing:

• POLR3E antibodies can detect changes in expression following viral infection

• Studies have shown that both DNA viruses (like HCMV) and RNA viruses (like Sindbis virus) induce POLR3E expression, suggesting a broader role in antiviral responses

• Western blotting with POLR3E antibodies can quantify these expression changes across different cell types and infection conditions

Investigating Immune Deficiency Associated with POLR3E Mutations:
A homozygous D40H mutation in POLR3E has been linked to impaired antiviral immune responses and recurrent viral infections . POLR3E antibodies can help study this connection through:

• Comparing POLR3E protein levels and localization in cells with wild-type vs. mutant POLR3E

• Immunoprecipitation to examine how the mutation affects protein-protein interactions within the Pol III complex

• Assessing changes in POLR3E localization during viral infection

Mechanistic Studies:
POLR3E antibodies facilitate investigation of the molecular mechanisms by which Pol III contributes to innate immunity:

• The D40H mutation affects assembly of Pol III initiation complexes, which can be studied using immunoprecipitation with POLR3E antibodies

• Antibodies can help track the localization of POLR3E during viral infection and immune stimulation

• Co-immunoprecipitation can identify interaction partners specific to POLR3E's immune function

This research area represents an emerging frontier where POLR3E antibodies play a crucial role in connecting basic molecular mechanisms to clinical immune phenotypes.

How are anti-RNA polymerase III antibodies relevant to systemic sclerosis research, and what laboratory techniques are used to study them?

Anti-RNA polymerase III (anti-RNAP3) antibodies represent a distinct category of autoantibodies in systemic sclerosis (SSc) research, different from antibodies against POLR3E used as research tools. These autoantibodies target components of the RNA polymerase III complex and have significant clinical implications:

Clinical Relevance of Anti-RNAP3 Antibodies:

• Anti-RNAP3 antibodies are highly specific for SSc, included in the 2013 ACR/EULAR classification criteria

• Associated with rapid and diffuse cutaneous involvement, joint contractures, scleroderma renal crisis (SRC), gastric antral vascular ectasia (GAVE), and synchronous malignancies

• Geographical variation in prevalence exists: high (15-22%) in Northern Europe, North America, and Australia; low (3-10%) in Southern and Central Europe and Asia

Laboratory Methods for Anti-RNAP3 Detection:

• Immunoprecipitation (IP): Originally used for discovery, allows detection of antibodies against the entire RNA polymerase III complex

• Enzyme-linked immunosorbent assay (ELISA): More accessible commercial method for clinical testing

• Multiplex line immunoblot (LIA): Another commercial technique for antibody detection

Recent Advances in Anti-RNAP3 Research:
Research has shown evidence of epitope spreading (ES) in anti-RNAP3 positive patients, with important clinical correlations:

Longitudinal assessment of ES correlates with mRSS and shows potential as a disease activity biomarker .

Antibody Titer Significance:

• Higher anti-RNAP3 titers correlate more strongly with certain manifestations:

  • SRC correlates better with higher ELISA titers

  • mRSS is higher in patients with high anti-RNAP3 as measured by ELISA or stronger LIA reactivity

  • Association with GAVE is more evident in cases with higher antibody levels

• Reduction in antibody titer has been correlated with clinical improvement, either spontaneously or after immunosuppressive therapy, particularly rituximab

These findings highlight how laboratory techniques for studying anti-RNAP3 antibodies contribute to both clinical management and mechanistic understanding of SSc.

What are common challenges when using POLR3E antibodies, and how can researchers address them?

Researchers working with POLR3E antibodies may encounter several technical challenges. Here are common issues and recommended solutions:

High Background Signal:

• Cause: Insufficient blocking, non-specific binding, or too high primary antibody concentration

• Solution:

  • Increase blocking time (1-2 hours) with 5% BSA or milk

  • Optimize antibody dilution (titration series from 1:500 to 1:2000 for WB)

  • Include 0.1-0.3% Tween-20 in wash buffers

  • Pre-absorb antibody with non-specific proteins

Weak or No Signal:

• Cause: Insufficient antigen, inadequate antigen retrieval, or protein degradation

• Solution:

  • For IHC/IF, optimize antigen retrieval using high-pressure and temperature Tris-EDTA (pH 8.0)

  • Increase antibody concentration or incubation time

  • Ensure sample preparation preserves POLR3E (include protease inhibitors)

  • Use fresh samples and verified positive controls like PC-3 cells

Multiple Bands in Western Blot:

• Cause: Protein degradation, non-specific binding, or post-translational modifications

• Solution:

  • Use freshly prepared lysates with complete protease inhibitor cocktail

  • Optimize sample denaturation conditions

  • Increase washing stringency

  • Compare with published validation data showing a single band at approximately 80 kDa

Inconsistent Results Across Applications:

• Cause: Different epitope accessibility in different techniques

• Solution:

  • Consider antibodies targeting different regions of POLR3E for specific applications

  • Verify that the epitope region is accessible in your application (the internal region is commonly targeted)

  • Compare results with multiple antibodies targeting different epitopes

Species Cross-Reactivity Issues:

• Cause: Sequence differences between species in the epitope region

• Solution:

  • Verify the antibody's species reactivity claims (human, mouse, rat are commonly validated)

  • For novel species applications, perform preliminary validation

  • Consider sequence alignment of the target epitope across species

Careful optimization and validation, as described above, will help ensure reliable and reproducible results when working with POLR3E antibodies.

How should researchers interpret changes in POLR3E expression levels in different experimental contexts?

Interpreting changes in POLR3E expression requires careful consideration of biological context and methodological controls:

Viral Infection Studies:

• Increased POLR3E expression has been observed following infection with both DNA viruses (HCMV) and RNA viruses (Sindbis virus)

• Interpretation: Suggests a broader role for POLR3E in antiviral responses beyond viral DNA sensing

• Validation approach: Compare with other viral infection models and verify using multiple detection methods (qPCR for mRNA, Western blot for protein)

Transcriptional Interference Studies:

• Deletion of an intronic antisense MIR element increases Polr3e expression at both mRNA (~1.5-fold) and protein levels

• Interpretation: Antisense transcription by Pol III can interfere with Pol II-mediated gene expression

• Validation approach: Confirm both pre-mRNA and mature mRNA changes, and correlate with protein level changes using POLR3E antibodies

Interpreting Expression Changes:
When observing changes in POLR3E levels, consider:

• Functional impact: Despite ~1.5-fold increases in POLR3E protein levels following MIR deletion, no corresponding increases in 5S rRNA, pre-tRNA Ile, and U6 snRNA were observed, suggesting POLR3E is not limiting for Pol III activity under those conditions

• Tissue/cell specificity: POLR3E expression patterns may vary across tissues; immunohistochemistry validation has been performed in colon and breast tissue samples

• Subcellular localization: Changes in total protein levels may not reflect alterations in functional nuclear pools of POLR3E; use immunofluorescence to assess localization changes

• Disease relevance: In patients with the D40H mutation in POLR3E, expression levels may be normal, but protein function in initiation complex assembly is impaired

Quantification Approaches:

• Western blot: Densitometry normalized to loading controls

• qPCR: ΔΔCt method for mRNA expression, with appropriate housekeeping gene controls

• Immunostaining: Mean fluorescence intensity or H-score for semi-quantitative analysis

Proper interpretation requires integrating these quantitative data with functional outcomes relevant to POLR3E's known roles in transcription and immunity.

What considerations are important when studying POLR3E in the context of autoimmune diseases?

When studying POLR3E in autoimmune contexts, particularly in relation to systemic sclerosis and anti-RNA polymerase III antibodies, researchers should consider several important factors:

Distinguishing Research Antibodies from Autoantibodies:

• Research antibodies against POLR3E are tools used to detect this protein

• Autoantibodies against RNA polymerase III components (anti-RNAP3) are produced by patients with certain autoimmune conditions, particularly systemic sclerosis

• These represent fundamentally different entities with different experimental approaches

Geographical and Demographic Considerations:

• The prevalence of anti-RNAP3 autoantibodies shows significant geographical variation:

  • High prevalence (15-22%) in Northern Europe, North America, and Australia

  • Low prevalence (3-10%) in Southern/Central Europe and Asia

• This geographical variation should be considered when designing patient cohorts or interpreting published studies

Antibody Titer and Clinical Correlations:

• Higher titers of anti-RNAP3 autoantibodies correlate more strongly with clinical manifestations:

  • Scleroderma renal crisis (SRC)

  • Higher modified Rodnan skin thickness score (mRSS)

  • Gastric antral vascular ectasia (GAVE)

• Methodological consideration: ELISA titers and multiplex line immunoblot (LIA) reactivity strength provide different but complementary information

Epitope Spreading Analysis:
Recent research has identified epitope spreading (ES) as an important phenomenon in systemic sclerosis:

Longitudinal assessment of ES correlates with disease activity and may serve as a biomarker .

Standardization Challenges:

• Different detection methods (immunoprecipitation, ELISA, LIA) may yield different results

• Cut-off values vary between assays (≥20 units has been used for RNApol3 antibody positivity)

• An optimal cut-off level of 27 units has been suggested for distinguishing SSc patients from non-SSc patients with positive RNApol3 antibodies

These considerations highlight the complexity of studying POLR3E in autoimmune contexts and the importance of methodological rigor and clinical correlation.

How might emerging technologies enhance the utility of POLR3E antibodies in research?

Emerging technologies offer exciting possibilities for expanding the utility of POLR3E antibodies in research:

Single-Cell Analysis Technologies:

• Integration of POLR3E antibodies with single-cell techniques like mass cytometry (CyTOF) or imaging mass cytometry

• This would allow simultaneous detection of POLR3E alongside other proteins at single-cell resolution

• Could reveal heterogeneity in POLR3E expression and localization across different cell populations, particularly relevant in immune contexts

Super-Resolution Microscopy:

• Applying techniques like STORM, PALM, or STED with fluorophore-conjugated POLR3E antibodies

• This would enable visualization of POLR3E's subnuclear localization at nanoscale resolution

• Could reveal spatial relationships between POLR3E/Pol III complexes and other nuclear structures during viral infection or transcriptional regulation

Proximity Labeling Approaches:

• Engineering POLR3E antibodies for proximity labeling techniques (BioID, APEX)

• Would enable identification of proteins in close proximity to POLR3E under different conditions

• Particularly valuable for studying POLR3E's role in viral sensing and immune signaling complexes

In Vivo Imaging Applications:

• Development of POLR3E antibody fragments suitable for in vivo imaging

• Could track POLR3E dynamics in animal models of viral infection or autoimmunity

• Potential application in monitoring treatment responses in relevant disease models

Multiomics Integration:

• Combining POLR3E antibody-based proteomics with transcriptomics and genomics

• Would provide integrated view of how POLR3E protein levels correlate with transcriptional changes

• Particularly relevant for understanding the functional consequences of mutations like D40H in POLR3E

These technological advances could significantly enhance our understanding of POLR3E's diverse functions in transcription, viral sensing, and disease contexts.

What are promising research areas for POLR3E antibody applications based on recent discoveries?

Recent discoveries have opened several promising research directions where POLR3E antibodies could play crucial investigative roles:

Innate Immunity and Viral Sensing:

• The discovery that POLR3E plays a role in innate antiviral immunity suggests antibodies could help elucidate:

  • The molecular mechanisms by which the D40H mutation in POLR3E impairs viral DNA sensing

  • How different viral infections modulate POLR3E expression and function

  • Potential therapeutic approaches targeting this pathway in immunodeficient patients

Transcriptional Interference Mechanisms:

• Building on findings that antisense Pol III transcription affects Polr3e expression :

  • Investigating similar mechanisms across other genes containing embedded Pol III elements

  • Exploring the regulatory potential of this mechanism in different cellular contexts

  • Examining how chromatin structure influences this interference

Autoimmune Disease Mechanisms:

• Following discoveries about epitope spreading in anti-RNAP3 antibodies in systemic sclerosis :

  • Investigating potential cross-reactivity between different subunits of the RNAP3 complex

  • Developing standardized assays for measuring epitope spreading as a disease biomarker

  • Exploring the immunological mechanisms behind the association between anti-RNAP3 antibodies and cancer in SSc

Cancer Research Applications:

• Given POLR3E antibody validation in cancer tissues (colon, breast) :

  • Investigating POLR3E expression patterns across cancer types and correlation with prognosis

  • Exploring functional consequences of POLR3E dysregulation in cancer cells

  • Examining connections between POLR3E function and cancer-associated metabolic changes

Therapeutic Development:

• POLR3E antibodies could facilitate:

  • Screening for compounds that modulate POLR3E function or expression

  • Monitoring responses to therapies targeting RNA polymerase III functions

  • Development of novel diagnostic approaches for diseases with POLR3E involvement

These research directions leverage recent discoveries about POLR3E's diverse biological roles and the growing arsenal of antibody-based research tools.

How might POLR3E research contribute to understanding other RNA polymerase III-related disorders?

POLR3E research has broader implications for understanding a spectrum of RNA polymerase III-related disorders, where antibodies serve as crucial investigative tools:

POLR3-Related Leukodystrophies:

• Several genetic disorders are caused by mutations in Pol III subunits (primarily POLR3A and POLR3B)

• POLR3E antibodies could help investigate:

  • Whether POLR3E function is altered in these conditions despite not being the primary mutation site

  • How mutations in other subunits affect POLR3E incorporation into the Pol III complex

  • Whether POLR3E could be a therapeutic target in these disorders

Other Immunodeficiency Syndromes:

• The D40H mutation in POLR3E causes immunodeficiency characterized by recurrent viral infections

• This suggests research applications for POLR3E antibodies in:

  • Screening patients with unexplained viral susceptibility for POLR3E expression/localization abnormalities

  • Investigating potential POLR3E involvement in other immunodeficiency syndromes

  • Developing diagnostic assays for POLR3E-related immune disorders

Additional Autoimmune Connections:

• Beyond systemic sclerosis, POLR3E antibodies could explore:

  • Potential involvement of Pol III dysregulation in other autoimmune conditions

  • Whether subclinical alterations in POLR3E function precede autoimmune manifestations

  • Connections between viral infections, POLR3E function, and autoimmunity development

Mechanistic Understanding of Disease:

• POLR3E research contributes to fundamental understanding of how Pol III dysfunction leads to disease:

  • In viral sensing contexts, POLR3E antibodies help elucidate how the D40H mutation affects initiation complex assembly

  • In transcriptional contexts, they reveal how Pol III activity influences expression of other genes

  • These mechanistic insights could inform therapeutic approaches for multiple disorders

Biomarker Development:

• The discovery that epitope spreading of anti-RNAP3 antibodies correlates with disease manifestations in SSc suggests:

  • Potential for similar biomarker approaches in other disorders

  • Development of standardized assays for monitoring disease progression and treatment response

  • Integration of POLR3E-related markers into comprehensive disease assessment panels

These research directions highlight how POLR3E antibodies contribute to a broader understanding of Pol III-related disorders, potentially leading to improved diagnostics and therapies.